Fingolimod

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

TASCENSO ODT — CYCLE, approved 2026-06-29 (NDA214962).

Most reported adverse events (US / FAERS)

68,820 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

10,878

multiple sclerosis relapse

7,803

headache

7,308

dizziness

5,413

Medicines containing this active substance

1 medicines

Fingolimod Mylan

Application withdrawn

🇺🇸 Also approved in the US (FDA)

TASCENSO ODT — CYCLE, approved 2026-06-29 (NDA214962).

Most reported adverse events (US / FAERS)

68,820 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

10,878

multiple sclerosis relapse

7,803

headache

7,308

dizziness

5,413

white blood cell count decreased

4,005

gait disturbance

3,886

hypoaesthesia

3,804

lymphocyte count decreased

3,594

fall

3,507

nausea

3,451

drug ineffective

3,170

malaise

3,150

memory impairment

2,984

pain

2,954

central nervous system lesion

2,913